CYPROHEPTADINE HCL (cyproheptadine hcl)

There are 0 contraindications.

There are 6 severe contraindications. Adequate patient monitoring is recommended for safer drug use.

Severe List
Angle-closure glaucoma
Benign prostatic hyperplasia
Bladder outflow obstruction
Chronic idiopathic constipation
Stenosing peptic ulcer
Urinary retention

There are 6 moderate contraindications. Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.

Moderate List
Coronary artery disease
Hypertension
Hyperthyroidism
Ocular hypertension
Pyloroduodenal obstruction
Seizure disorder

There are 5 severe adverse reactions.

More Frequent	Less Frequent
None.	None.

Rare/Very Rare
Abnormal hepatic function tests Anticholinergic toxicity Blood dyscrasias Cholestasis Drug-induced hepatitis

There are 22 less severe adverse reactions.

More Frequent	Less Frequent
Drowsy Thick bronchial secretions	None.

Rare/Very Rare
Abdominal pain with cramps Accidental fall Acute cognitive impairment Blurred vision Dizziness Dry nose Dry throat Dysuria Excitement Hyperhidrosis Increased appetite Nervousness Nightmares Skin photosensitivity Skin rash Tachycardia Tinnitus Visual changes Weight gain Xerostomia

Reproduction studies in rabbits, mice, and rats using oral or subcutaneous cyproheptadine hydrochloride dosages up to 32 times the maximum recommended human oral dosage have not revealed evidence of harm to the fetus. Although the drug has been fetotoxic in rats when administered intraperitoneally at dosages 4 times the maximum recommended human oral dosage, experience in a limited number of women who received cyproheptadine orally during the first, second, and/or third trimesters of pregnancy did not reveal evidence of an increased risk of fetal abnormalities, nor were teratogenic effects observed in neonates born to these women. No evidence of adverse fetal effect was evident in an infant born to a woman who had received 12 mg of cyproheptadine hydrochloride daily throughout pregnancy for the treatment of Cushing's syndrome; the infant developed normally until 4 months of age when he developed gastroenteritis and died. Nevertheless, because the reported experience to date in humans cannot exclude the possibility of adverse fetal effects of the drug, cyproheptadine should be used during pregnancy only when clearly needed.

It is not known whether cyproheptadine hydrochloride is distributed into milk. Because of the potential for serious adverse reactions to cyproheptadine in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.

No enhanced Geriatric Use information available for this drug.